Detalhe da pesquisa
1.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol
; 156(1): 38-44, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31699415
2.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Gynecol Oncol
; 153(3): 535-540, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979589
3.
Capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study.
Int J Gynecol Cancer
; 29(2): 272-276, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30636709
4.
Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Oncology
; 94(1): 1-6, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-28869928
5.
Locally Advanced Cervical Cancer: Is a Trimodality Treatment a Safe and Effective Approach?
Oncology
; 95(4): 239-245, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29920481
6.
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Oncology
; 95(1): 1-7, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29510410
7.
Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study.
Int J Gynecol Cancer
; 28(9): 1706-1713, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30376554
8.
Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
Ann Surg Oncol
; 24(11): 3396-3405, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28795373
9.
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
Gynecol Oncol
; 144(1): 90-95, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27817933
10.
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Gynecol Oncol
; 144(2): 256-259, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993479
11.
The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
Int J Gynecol Cancer
; 27(9): 1856-1862, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29064913
12.
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.
Gynecol Oncol
; 143(2): 443-447, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27481579
13.
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 16(5): 561-8, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25882986
14.
Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.
Int J Gynecol Cancer
; 29(1): 153-157, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640698
15.
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Target Oncol
; 16(1): 59-68, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369704
16.
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
Tumori
; 105(4): 282-287, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917765
17.
RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Eur J Obstet Gynecol Reprod Biol
; 237: 93-99, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31029972
18.
Rucaparib: a new treatment option for ovarian cancer.
Expert Opin Pharmacother
; 19(7): 765-771, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672168
19.
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Drug Des Devel Ther
; 12: 1501-1509, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29881257
20.
The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
Expert Opin Drug Saf
; 16(6): 687-696, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28471247